Samar F. Miski

Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies

Tagyedeen H. Shoaib, Walaa Ibraheem, Mohammed Abdelrahman et al. · PLoS ONE · 2023 · 26 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Repositioning gemigliptin for the alleviation of thioacetamide-induced liver fibrosis in rats: Targeting TLR4/MAPK, SIRT1/AMPK/Nrf2, PI3K/AKT/mTOR axis and apoptosis

Riyadh S. Almalki, Malaz Gazzaz, Samar F. Miski et al. · European Journal of Pharmaceutical Sciences · 2025 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Introducing of novel class of pyrano[2,3- <i>c</i> ]pyrazole-5-carbonitrile analogs with potent antimicrobial activity, DNA gyrase inhibition, and prominent pharmacokinetic and CNS toxicity profiles supported by molecular dynamic simulation

Mohammed Almaghrabi, Arafa Musa, Ahmed K. B. Aljohani et al. · Journal of Biomolecular Structure and Dynamics · 2023 · 15 citations

Life Sciences, Microbiology, Pharmacology +13

Improving the targeting and therapeutic efficacy of anastrazole for the control of breast cancer: In vitro and in vivo characterization

Rana El-Bakry, Dina M. Mahmoud, Mary Eskander Attia et al. · International Journal of Pharmaceutics · 2024 · 12 citations

Medicine, Oncology, Pharmacology +16

Design of new Mcl-1 inhibitors for cancer using fragments hybridization, molecular docking, and molecular dynamics studies

Abdulrahim A. Alzain, Fatima A. Elbadwi, Rua M. Mukhtar et al. · Journal of Biomolecular Structure and Dynamics · 2023 · 10 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17